Replimune Group, Inc. (REPL)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Sushil Patel Ph.D.
|
CEO & Director | 1.02M | -- | 1971 |
|
Ms. Emily Luisa Hill
|
Chief Financial Officer | 728.32k | -- | 1980 |
|
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D.
|
Chief Medical Officer | 748.53k | -- | 1966 |
|
Mr. Philip Astley-Sparke F.S.A.
|
Executive Chairman | 960.52k | -- | 1971 |
Replimune Group, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 465
Description
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Corporate Governance
Upcoming Events
October 28, 2026 at 12:30 PM UTC
Replimune Group, Inc. Earnings Date
